The aim of this technology assessment, which has been commissioned by NICE through the NIHR SR Programme as part of the NICE Single Technology Appraisal process, is to review the submission received from the Medtronic on the clinical and cost-effectiveness evidence of TYRX Absorbable Antibacterial Envelope (Ledaga®) for preventing infection from cardiac implantable electronic devices in adults. The primary source of clinical effectiveness evidence submitted by Medtronic consists of a RCT (WRAP-IT trial) comparing TYRX versus no TYRX. The Aberdeen HTA Group acts as the Evidence Review Group (ERG) for this technology appraisal and provides an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from the company and the ERG’s critique, NICE will release appropriate clinical guidance. For more information see: https://www.nice.org.uk/guidance/indevelopment/gid-ta10370
Contacts
- Miriam Brazzelli; m.brazzelli@abdn.ac.uk